ALDH1A1 and prostate carcinoma: Similarly, TOPO-METRO as a single agent and combination TOPO-METRO+CONV-DTX treatment downregulated ALDH1 protein (70%, 46%, respectively) in mCRPC/NEPC (PC-3M) cell line and (50%, 26%, respectively) in taxane-resistant mCRPC/NEPC (DUTXR) aggressive prostate cancer subtypes.